Conversely, offsetting factors – including the negligible response of ERK1/2 and AKT and other EGFR-responsive genes including MYC and VEGFA [63] (Figure 9B) to attenuated p-EGFR levels in SW1990 cells – suggest that a compound such as 1,3,4-O-Bu3ManNAc is unlikely to comprise a “stand alone” drug for advanced stage pancreatic cancers. The gene discussed is MAPK3; the disease is pancreatic neoplasm.